HPV vaccination: one crore doses administered in nine months
India has administered more than one crore HPV vaccine doses in less than nine months. That equals nearly 87% of the annual target cohort of 14-year-old girls in the national cervical cancer prevention campaign, launched in February 2026. The Union Health Ministry reported the figures on November 21, 2026. Uttar Pradesh has vaccinated the most girls in absolute numbers, with more than 29.33 lakh, followed by Bihar with 13.70 lakh and Gujarat with 7.75 lakh. Six states—Gujarat, Uttar Pradesh, Andhra Pradesh, Mizoram, Madhya Pradesh and Bihar—have reached 100% of their identified target populations. The vaccine is offered free and voluntarily to eligible girls at designated government health facilities, with parental consent. U-WIN supports tracking, monitoring, slot booking and digital certificates. The Ministry says sessions are medically supervised, with arrangements to manage adverse events. The figures show the campaign is close to its annual target, though coverage varies by state.
How many HPV vaccine doses has India administered, and how close is that to its annual target?
India has administered more than one crore HPV vaccine doses in less than nine months. That equals nearly 87% of the annual target cohort of 14-year-old girls in the national cervical cancer prevention campaign, launched in February 2026. The Union Health Ministry reported the figures on November 21, 2026.
Uttar Pradesh has vaccinated the most girls in absolute numbers, with more than 29.33 lakh, followed by Bihar with 13.70 lakh and Gujarat with 7.75 lakh. Six states—Gujarat, Uttar Pradesh, Andhra Pradesh, Mizoram, Madhya Pradesh and Bihar—have reached 100% of their identified target populations.
The vaccine is offered free and voluntarily to eligible girls at designated government health facilities, with parental consent. U-WIN supports tracking, monitoring, slot booking and digital certificates. The Ministry says sessions are medically supervised, with arrangements to manage adverse events. The figures show the campaign is close to its annual target, though coverage varies by state.
Which states have vaccinated the most girls, and how does coverage vary across the country?
Coverage is not even across the country: some states have vaccinated all of their identified target population, while others remain below that mark. The Ministry’s figures report both total numbers of girls vaccinated and percentages of identified targets, which show different parts of the campaign’s progress.
Uttar Pradesh leads in absolute numbers, with more than 29.33 lakh girls vaccinated, followed by Bihar at 13.70 lakh and Gujarat at 7.75 lakh. Gujarat, Uttar Pradesh, Andhra Pradesh, Mizoram, Madhya Pradesh and Bihar have each reached 100% coverage of their identified target populations. Assam has recorded 95.63%, Telangana 95.28%, Karnataka 93.16% and Uttarakhand 90.17%.
Several other states have passed 70%: Chhattisgarh and Rajasthan are above 80%, while Kerala, Tamil Nadu, Odisha, and Dadra and Nagar Haveli and Daman and Diu are above 70%. The last recorded 72.99%. These differences make ongoing monitoring and local outreach important as the campaign continues toward its annual target.
What is HPV, and how can it lead to cervical cancer?
The article does not define HPV. In general, HPV stands for human papillomavirus, a large family of viruses that infect the skin and moist linings of the body. Many infections go away on their own, but some types can persist. The vaccine campaign in the article aims to help prevent cervical cancer.
Some persistent HPV infections affect cells in the cervix, the lower part of the uterus. Over time, high-risk types can cause cell changes that may develop into cancer if they are not detected and treated. HPV is common, and infection often has no obvious symptoms, so a person may not know they have it.
The article reports that India’s campaign provides a single vaccine dose to eligible 14-year-old girls, with parental consent and medical supervision. It does not specify which HPV types the campaign vaccine targets or explain the biological pathway from infection to cancer. In general, HPV vaccination is a preventive measure; it does not treat an infection or cancer that is already present.
Why is the vaccine offered to girls around age 14?
The article identifies 14-year-old girls as the campaign’s target cohort but does not state why the government selected that age. In general, HPV vaccines are preventive, so health programmes aim to offer them before a person is exposed to HPV. This is why vaccination is commonly recommended in early adolescence.
The article says the campaign offers a single dose free and voluntarily to eligible girls at designated government health facilities, with parental consent. Sessions take place under medical supervision. The Ministry reports that frontline workers, including teachers, ASHAs and ANMs, have worked with parents and communities to encourage informed participation.
The programme’s exact age policy and its rationale are not detailed in the text, so the general explanation should not be mistaken for a stated government reason. The campaign’s current target is 14-year-old girls, and its annual progress is measured against that cohort. U-WIN lets parents book vaccination slots and access digital certificates, supporting participation and record-keeping.
How could widespread HPV vaccination affect cervical cancer rates in the future?
The article presents HPV vaccination as part of India’s cervical cancer prevention campaign. In general, vaccination can reduce infections from the HPV types it targets, and preventing persistent infections can reduce the number of related precancerous changes and cancers that develop later. The effect on cancer rates would take time to appear.
The campaign is offering a single vaccine dose free and voluntarily to eligible 14-year-old girls, with parental consent. More than one crore doses have been administered in less than nine months, reaching nearly 87% of the annual target cohort. Those figures describe vaccination progress, not a measured decline in cervical cancer cases.
The article gives no forecast for how much cancer rates may fall, nor does it provide cancer outcome data. Future impact would depend on sustained vaccination and other prevention and care measures. The current campaign also uses U-WIN to track beneficiaries and vaccination records, while medical supervision and adverse-event arrangements accompany sessions. These systems support delivery, but the article reports no long-term health outcomes yet.
How does the HPV vaccine help protect someone from infection?
The article does not describe the vaccine’s biological mechanism. In general, an HPV vaccine presents the immune system with harmless material resembling parts of the virus. It does not cause HPV infection. This exposure helps the body prepare defenses before it encounters the actual virus.
The immune system can then produce antibodies that recognize the targeted HPV types. If a vaccinated person later encounters one of those types, the antibodies can help block infection. The vaccine is preventive: it does not clear an HPV infection that is already present or treat cervical cancer. The article does not identify the vaccine product used in the campaign.
India’s campaign provides a single dose free and voluntarily to eligible 14-year-old girls at designated government health facilities, with parental consent. The Ministry says vaccination sessions are medically supervised and include arrangements for managing adverse events. U-WIN supports beneficiary tracking and digital records. These are delivery and monitoring details; the article does not report immune-response data or explain which HPV types the vaccine covers.
How does the immune system learn to recognize and fight a virus after vaccination?
The article does not explain how immune memory forms. In general, vaccination exposes the immune system to a harmless form or part of a pathogen, or instructions for making that part. This lets the body respond without having to face the disease itself. Different vaccines use different methods, and the article does not say which mechanism applies to the campaign’s HPV vaccine.
During this exposure, immune cells recognize the vaccine material as foreign. Some B cells can make antibodies that bind to it, while other immune cells help coordinate the response. Some of these cells remain as memory cells. If the body later encounters the matching virus, these cells can respond more quickly and strongly.
India’s campaign offers a single dose to eligible 14-year-old girls, with parental consent, and conducts sessions under medical supervision. U-WIN records vaccination and supports beneficiary tracking. These details describe how the programme delivers and documents doses, not how each recipient’s immune system responds. The article provides no antibody or immune-memory measurements.
This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.
Read more in the JupiteX app
Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.
Or read more news on the web